The estimated Net Worth of Douglas Kakdl, L.P.Neuro Li... is at least $527 Million dollars as of 12 December 2017. Douglas Li owns over 275,000 units of Denali Therapeutics Inc stock worth over $527,044,473 and over the last 7 years Douglas sold DNLI stock worth over $0.
Douglas has made over 1 trades of the Denali Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Douglas bought 275,000 units of DNLI stock worth $4,950,000 on 12 December 2017.
The largest trade Douglas's ever made was buying 275,000 units of Denali Therapeutics Inc stock on 12 December 2017 worth over $4,950,000. On average, Douglas trades about 275,000 units every 0 days since 2017. As of 12 December 2017 Douglas still owns at least 19,462,499 units of Denali Therapeutics Inc stock.
You can see the complete history of Douglas Li stock trades at the bottom of the page.
Over the last 7 years, insiders at Denali Therapeutics Inc have traded over $438,930,443 worth of Denali Therapeutics Inc stock and bought 275,000 units worth $4,950,000 . The most active insiders traders include Llc Fmr, Douglas Kakdl, L.P.Crestlin... und Jay T Flatley. On average, Denali Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of $1,606,006. The most recent stock trade was executed by Vicki L Sato on 3 September 2024, trading 3,080 units of DNLI stock currently worth $77,000.
denali therapeutics inc. (“denali”) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including alzheimer’s disease, parkinson’s disease, als and others. denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. founding investors include fidelity biosciences, arch venture partners, flagship ventures and the alaska permanent fund (represented by crestline investors).
Denali Therapeutics Inc executives and other stock owners filed with the SEC include: